➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Last Updated: August 1, 2021

DrugPatentWatch Database Preview

Patent: 10,058,610

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 10,058,610
Title:Methods for treating cancer by administering humanized pan-HER antibody compositions
Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.
Inventor(s): Lantto; Johan (Lund, SE), Andersen; Kim Vilbour (Bronshoj, DK), Andersen; Peter Sejer (Vanlose, DK), Strandh; Magnus (Malmo, SE), Koefoed; Klaus (Kobenhavn S, DK), Nielsen; Lars Sogaard (Niva, DK), Pedersen; Mikkel Wandahl (Alleroed, DK), Jacobsen; Helle (Virum, DK), Kragh; Michael (Copenhagen, DK), Kjaer; Ida (Copenhagen, DK), Poulsen; Thomas Tuxen (Dyssegaard, DK)
Assignee: Symphogen A/S (Ballerup, DK)
Application Number:15/350,801
Patent Claims:see list of patent claims

Details for Patent 10,058,610

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28 ⤷  Try it Free Symphogen A/S (Ballerup, DK) 2032-05-02 RX search
Genentech PERJETA pertuzumab VIAL; SINGLE-USE 125409 001 2012-06-08 ⤷  Try it Free Symphogen A/S (Ballerup, DK) 2032-05-02 RX search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18 ⤷  Try it Free Symphogen A/S (Ballerup, DK) 2032-05-02 RX Orphan search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25 ⤷  Try it Free Symphogen A/S (Ballerup, DK) 2032-05-02 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 10,058,610

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2013164689 ⤷  Try it Free
United States of America 2015086478 ⤷  Try it Free
United States of America 2017165365 ⤷  Try it Free
United States of America 2018344846 ⤷  Try it Free
United States of America 9527913 ⤷  Try it Free
Mexico 2014013213 ⤷  Try it Free
Mexico 358728 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.